Preliminary experiments using 10–100 μg/ml of AA and 10–1000 IU/ml of IFN-α resulted in >90% cell viability at 48–72 hours of treatment, in both NDs and HAM/TSP patients (data not shown). This evidence concerns the gene IFNA2 and tropical spastic paraparesis.